title: Testosterone-induced relaxation of coronary arteries: activation of BKCa channels via the cGMP-dependent protein kinase.
abstract: Androgens are reported to have both beneficial and detrimental effects on human cardiovascular health. The aim of this study was to characterize nongenomic signaling mechanisms in coronary artery smooth muscle (CASM) and define the ionic basis of testosterone (TES) action. TES-induced relaxation of endothelium-denuded porcine coronary arteries was nearly abolished by 20 nM iberiotoxin, a highly specific inhibitor of large-conductance, calcium-activated potassium (BK(Ca)) channels. Molecular patch-clamp studies confirmed that nanomolar concentrations of TES stimulated BK(Ca) channel activity by ∼100-fold and that inhibition of nitric oxide synthase (NOS) activity by N(G)-monomethyl-L-arginine nearly abolished this effect. Inhibition of nitric oxide (NO) synthesis or guanylyl cyclase activity also attenuated TES-induced coronary artery relaxation but did not alter relaxation due to 8-bromo-cGMP. Furthermore, we detected TES-stimulated NO production in porcine coronary arteries and in human CASM cells via stimulation of the type 1 neuronal NOS isoform. Inhibition of the cGMP-dependent protein kinase (PKG) attenuated TES-stimulated BK(Ca) channel activity, and direct assay determined that TES increased activity of PKG in a concentration-dependent fashion. Last, the stimulatory effect of TES on BK(Ca) channel activity was mimicked by addition of purified PKG to the cytoplasmic surface of a cell-free membrane patch from CASM myocytes (∼100-fold increase). These findings indicate that TES-induced relaxation of endothelium-denuded coronary arteries is mediated, at least in part, by enhanced NO production, leading to cGMP synthesis and PKG activation, which, in turn, opens BK(Ca) channels. These findings provide a molecular mechanism that could help explain why androgens have been reported to relax coronary arteries and relieve angina pectoris.
authors.affiliation: Department of Physiology & Biophysics, Wright State University School of Medicine, Dayton, Ohio, USA.
authors.forename: Viju
authors.initials: V
authors.lastname: Deenadayalu
authors.forename: Yashoda
authors.initials: Y
authors.lastname: Puttabyatappa
authors.forename: Alexander T
authors.initials: AT
authors.lastname: Liu
authors.forename: John N
authors.initials: JN
authors.lastname: Stallone
authors.forename: Richard E
authors.initials: RE
authors.lastname: White
mesh_terms: D000818:Animals; D003331:Coronary Vessels / Q000201:enzymology; D017869:Cyclic GMP-Dependent Protein Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D004789:Enzyme Activation; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005260:Female; D006162:Guanylate Cyclase / Q000037:antagonists & inhibitors / Q000378:metabolism; D051036:Large-Conductance Calcium-Activated Potassium Channels / Q000037:antagonists & inhibitors / Q000378:metabolism*; D008297:Male; D008564:Membrane Potentials; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000201:enzymology*; D009569:Nitric Oxide / Q000378:metabolism; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors / Q000378:metabolism; D018408:Patch-Clamp Techniques; D010766:Phosphorylation; D015221:Potassium Channels / Q000494:pharmacology; D015398:Signal Transduction; D013552:Swine; D013739:Testosterone / Q000378:metabolism*; D013997:Time Factors; D014664:Vasodilation / Q000187:drug effects
chemical_list: D004791:Enzyme Inhibitors; D051036:Large-Conductance Calcium-Activated Potassium Channels; D015221:Potassium Channels; D009569:Nitric Oxide; D013739:Testosterone; D019001:Nitric Oxide Synthase; D017869:Cyclic GMP-Dependent Protein Kinases; D006162:Guanylate Cyclase
references.citation: J Cardiovasc Pharmacol. 2002 Jun;39(6):814-23
references.pmid: 12021575
references.citation: Clin Sci (Lond). 2006 Oct;111(4):251-2
references.pmid: 16681461
references.citation: Endocr Rev. 2003 Jun;24(3):313-40
references.pmid: 12788802
references.citation: J Cardiovasc Pharmacol. 1999 Nov;34(5):619-27
references.pmid: 10547076
references.citation: Br J Pharmacol. 2002 Feb;135(3):735-40
references.pmid: 11834621
references.citation: Cardiovasc Res. 2000 Mar;45(4):1010-8
references.pmid: 10728427
references.citation: J Biol Chem. 1951 Nov;193(1):265-75
references.pmid: 14907713
references.citation: Arch Intern Med. 2007 Nov 12;167(20):2249-54
references.pmid: 17998499
references.citation: Am J Physiol Heart Circ Physiol. 2010 May;298(5):H1301-7
references.pmid: 20228257
references.citation: Eur J Pharmacol. 2010 Aug 25;640(1-3):94-101
references.pmid: 20444426
references.citation: J Pharmacol Exp Ther. 2009 Jun;329(3):850-5
references.pmid: 19293389
references.citation: J Endocrinol Invest. 2002 May;25(5):455-8
references.pmid: 12035943
references.citation: Cell Calcium. 2007 May;41(5):467-77
references.pmid: 17084891
references.citation: Am J Physiol Heart Circ Physiol. 2007 Jul;293(1):H314-21
references.pmid: 17351066
references.citation: Am J Physiol Heart Circ Physiol. 2005 Oct;289(4):H1468-75
references.pmid: 16162867
references.citation: Endocr Rev. 2003 Apr;24(2):183-217
references.pmid: 12700179
references.citation: Biochem Biophys Res Commun. 1987 Jan 30;142(2):436-40
references.pmid: 3028414
references.citation: Am J Physiol. 1997 Jun;272(6 Pt 2):H2765-73
references.pmid: 9227556
references.citation: Cardiovasc Res. 2002 Feb 15;53(3):650-61
references.pmid: 11861036
references.citation: Am J Physiol Heart Circ Physiol. 2004 Nov;287(5):H2091-8
references.pmid: 15242831
references.citation: Endocrinology. 2010 Apr;151(4):1822-8
references.pmid: 20194727
references.citation: J Pharmacol Sci. 2007 Mar;103(3):309-16
references.pmid: 17380036
references.citation: Circulation. 1995 Feb 15;91(4):1154-60
references.pmid: 7850954
references.citation: Endocrinology. 2008 May;149(5):2517-26
references.pmid: 18276759
references.citation: Biochem Biophys Res Commun. 2004 May 28;318(2):503-6
references.pmid: 15120629
references.citation: Int J Impot Res. 2007 Mar-Apr;19(2):176-82
references.pmid: 16943795
references.citation: J Biol Chem. 1977 Jul 25;252(14):4888-94
references.pmid: 194899
references.citation: Circ Res. 2000 Apr 28;86(8):897-905
references.pmid: 10785513
references.citation: Eur J Pharmacol. 1999 Apr 29;371(2-3):169-78
references.pmid: 10357254
references.citation: Eur J Pharmacol. 2008 Sep 28;593(1-3):87-91
references.pmid: 18662681
references.citation: Prog Cardiovasc Dis. 1998 Jul-Aug;41(1):1-15
references.pmid: 9717856
references.citation: Circulation. 1996 Nov 15;94(10):2614-9
references.pmid: 8921808
references.citation: Arterioscler Thromb Vasc Biol. 1999 Apr;19(4):1034-40
references.pmid: 10195933
references.citation: J Med Chem. 1997 Nov 21;40(24):3869-70
references.pmid: 9397167
references.citation: J Sex Med. 2008 Apr;5(4):822-832
references.pmid: 18208499
references.citation: J Appl Physiol (1985). 2001 Dec;91(6):2742-50
references.pmid: 11717242
references.citation: Circulation. 2007 Dec 4;116(23):2694-701
references.pmid: 18040028
references.citation: J Cardiovasc Pharmacol. 1999 May;33(5):691-7
references.pmid: 10226854
references.citation: Circ Res. 2000 Oct 13;87(8):677-82
references.pmid: 11029403
references.citation: Circ Res. 1995 Nov;77(5):936-42
references.pmid: 7554147
references.citation: Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4592-7
references.pmid: 12672953
references.citation: Pharmacol Res. 2010 Jan;61(1):62-70
references.pmid: 19573602
references.citation: Ther Clin Risk Manag. 2009 Jun;5(3):427-48
references.pmid: 19707253
references.citation: Am J Physiol Heart Circ Physiol. 2001 Oct;281(4):H1720-7
references.pmid: 11557563
references.citation: J Clin Oncol. 2006 Sep 20;24(27):4448-56
references.pmid: 16983113